Yang Liyuan,Gu Song,Wang Jing,et al.Research advances of m6A modification in hepatoblastoma[J].Journal of Clinical Pediatric Surgery,,22():1130-1134.[doi:10.3760/cma.j.cn101785-202209040-007]
Click Copy

Research advances of m6A modification in hepatoblastoma

References:

[1] Allan BJ,Parikh PP,Diaz S,et al.Predictors of survival and incidence of hepatoblastoma in the paediatric population[J].HPB (Oxford),2013,15(10):741-746.DOI:10.1111/hpb.12112.
[2] Nagae G,Yamamoto S,Fujita M,et al.Genetic and epigenetic basis of hepatoblastoma diversity[J].Nat Commun,2021,12(1):5423.DOI:10.1038/s41467-021-25430-9.
[3] Aguiar T,Teixeira A,Scliar MO,et al.Unraveling the genetic architecture of hepatoblastoma risk:birth defects and increased burden of germline damaging variants in gastrointestinal/renal cancer predisposition and DNA repair genes[J].Front Genet,2022,13:858396.DOI:10.3389/fgene.2022.858396.
[4] Cohen MM Jr.Beckwith-Wiedemann syndrome:historical,clinicopathological,and etiopathogenetic perspectives[J].Pediatr Dev Pathol,2005,8(3):287-304.DOI:10.1007/s10024-005-1154-9.
[5] Thomas D,Pritchard J,Davidson R,et al.Familial hepatoblastoma and APC gene mutations:renewed call for molecular research[J].Eur J Cancer,2003,39(15):2200-2204.DOI:10.1016/s0959-8049(03)00618-x.
[6] Boccaletto P,Stefaniak F,Ray A,et al.MODOMICS:a database of RNA modification pathways.2021 update[J].Nucleic Acids Res,2022,50(D1):D231-D235.DOI:10.1093/nar/gkab1083.
[7] Zhao BS,Roundtree IA,He C.Post-transcriptional gene regulation by mRNA modifications[J].Nat Rev Mol Cell Biol,2017,18(1):31-42.DOI:10.1038/nrm.2016.132.
[8] Desrosiers R,Friderici K,Rottman F.Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells[J].Proc Natl Acad Sci U S A,1974,71(10):3971-3975.DOI:10.1073/pnas.71.10.3971.
[9] Jia GF,Fu Y,Zhao X,et al.N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO[J].Nat Chem Biol,2011,7(12):885-887.DOI:10.1038/nchembio.687.
[10] Sun T,Wu RY,Ming L.The role of m6A RNA methylation in cancer[J].Biomed Pharmacother,2019,112:108613.DOI:10.1016/j.biopha.2019.108613.
[11] Zaccara S,Ries RJ,Jaffrey SR.Reading,writing and erasing mRNA methylation[J].Nat Rev Mol Cell Biol,2019,20(10):608-624.DOI:10.1038/s41580-019-0168-5.
[12] Meyer KD.DART-seq:an antibody-free method for global m6A detection[J].Nat Methods,2019,16(12):1275-1280.DOI:10.1038/s41592-019-0570-0.
[13] Tegowski M,Flamand MN,Meyer KD.scDART-seq reveals distinct m6A signatures and mRNA methylation heterogeneity in single cells[J].Mol Cell,2022,82(4):868-878.e10.DOI:10.1016/j.molcel.2021.12.038.
[14] Garalde DR,Snell EA,Jachimowicz D,et al.Highly parallel direct RNA sequencing on an array of nanopores[J].Nat Methods,2018,15(3):201-206.DOI:10.1038/nmeth.4577.
[15] Pratanwanich PN,Yao F,Chen Y,et al.Identification of differential RNA modifications from nanopore direct RNA sequencing with xPore[J].Nat Biotechnol,2021,39(11):1394-1402.DOI:10.1038/s41587-021-00949-w.
[16] K?rtel N,Rücklé C,Zhou Y,et al.Deep and accurate detection of m6A RNA modifications using miCLIP2 and m6Aboost machine learning[J].Nucleic Acids Res,2021,49(16):e92.DOI:10.1093/nar/gkab485.
[17] Perugorria MJ,Olaizola P,Labiano I,et al.Wnt-β-catenin signalling in liver development,health and disease[J].Nat Rev Gastroenterol Hepatol,2019,16(2):121-136.DOI:10.1038/s41575-018-0075-9.
[18] Crippa S,Ancey PB,Vazquez J,et al.Mutant CTNNB1 and histological heterogeneity define metabolic subtypes of hepatoblastoma[J].EMBO Mol Med,2017,9(11):1589-1604.DOI:10.15252/emmm.201707814.
[19] López-Terrada D,Gunaratne PH,Adesina AM,et al.Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors[J].Hum Pathol,2009,40(6):783-794.DOI:10.1016/j.humpath.2008.07.022.
[20] Ashihara E,Takada T,Maekawa T.Targeting the canonical Wnt/β-catenin pathway in hematological malignancies[J].Cancer Sci,2015,106(6):665-671.DOI:10.1111/cas.12655.
[21] Liu L,Wang J,Sun GF,et al.m6A mRNA methylation regulates CTNNB1 to promote the proliferation of hepatoblastoma[J].Mol Cancer,2019,18(1):188.DOI:10.1186/s12943-019-1119-7.
[22] Yang WS,SriRamaratnam R,Welsch ME,et al.Regulation of ferroptotic cancer cell death by GPX4[J].Cell,2014,156(1/2):317-331.DOI:10.1016/j.cell.2013.12.010.
[23] Liu L,He JT,Sun GF,et al.The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma[J].Clin Transl Med,2022,12(5):e778.DOI:10.1002/ctm2.778.
[24] Ruan TY,He XT,Yu J,et al.MicroRNA-186 targets Yes-associated protein 1 to inhibit Hippo signaling and tumorigenesis in hepatocellular carcinoma[J].Oncol Lett,2016,11(4):2941-2945.DOI:10.3892/ol.2016.4312.
[25] von Frowein J,Pagel P,Kappler R,et al.MicroRNA-492 is processed from the keratin 19 gene and up-regulated in metastatic hepatoblastoma[J].Hepatology,2011,53(3):833-842.DOI:10.1002/hep.24125.
[26] 成英杰,单慈,石寒菡,等.MicroRNAs在肝母细胞瘤诊断、鉴别诊断及预后评估中的研究进展[J].临床小儿外科杂志,2019,18(8):660-663.DOI:10.3969/j.issn.1671-6353.2019.08.009. Cheng YJ,Shan C,Shi HH,et al.Research advances of microRNAs in the diagnosis,differential diagnosis and prognostic evaluation of hepatoblastoma[J].J Clin Ped Sur,2019,18(8):660-663.DOI:10.3969/j.issn.1671-6353.2019.08.009.
[27] Cui XC,Wang ZF,Li JH,et al.Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/β-catenin signalling pathway[J].Cell Prolif,2020,53(3):e12768.DOI:10.1111/cpr.12768.
[28] Neviani P,Wise PM,Murtadha M,et al.Natural killer-derived exosomal miR-186 inhibits neuroblastoma growth and immune escape mechanisms[J].Cancer Res,2019,79(6):1151-1164.DOI:10.1158/0008-5472.CAN-18-0779.
[29] Gou YL,Zhai FB,Zhang L,et al.RUNX3 regulates hepatocellular carcinoma cell metastasis via targeting miR-186/E-cadherin/EMT pathway[J].Oncotarget,2017,8(37):61475-61486.DOI:10.18632/oncotarget.18424.
[30] Li LL,Xie RR,Lu GR.Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma[J].Biosci Rep,2021,41(6):BSR20210760.DOI:10.1042/BSR20210760.
[31] Wang HX,Meng QK,Ma B.Characterization of the prognostic m6A-related lncRNA signature in gastric cancer[J].Front Oncol,2021,11:630260.DOI:10.3389/fonc.2021.630260.
[32] Tu ZW,Wu L,Wang P,et al.N6-methylandenosine-related lncRNAs are potential biomarkers for predicting the overall survival of lower-grade glioma patients[J].Front Cell Dev Biol,2020,8:642.DOI:10.3389/fcell.2020.00642.
[33] Zhang W,Liang F,Li QF,et al.LncRNA MIR205HG accelerates cell proliferation,migration and invasion in hepatoblastoma through the activation of MAPK signaling pathway and PI3K/AKT signaling pathway[J].Biol Direct,2022,17(1):2.DOI:10.1186/s13062-021-00309-3.
[34] Cui XC,Wang ZF,Liu LW,et al.The long non-coding RNA ZFAS1 sponges miR-193a-3p to modulate hepatoblastoma growth by targeting RALY via HGF/c-Met pathway[J].Front Cell Dev Biol,2019,7:271.DOI:10.3389/fcell.2019.00271.
[35] Chen HT,Duan F,Wang M,et al.Polymorphisms in METTL3 gene and hepatoblastoma risk in Chinese children:a seven-center case-control study[J].Gene,2021,800:145834.DOI:10.1016/j.gene.2021.145834.
[36] Chen HT,Chen Z,Wang M,et al.METTL14 gene polymorphisms influence hepatoblastoma predisposition in Chinese children:evidences from a seven-center case-control study[J].Gene,2022,809:146050.DOI:10.1016/j.gene.2021.146050.
[37] Zhuo ZJ,Hua RX,Chen Z,et al.WTAP gene variants confer hepatoblastoma susceptibility:a seven-center case-control study[J].Mol Ther Oncolytics,2020,18:118-125.DOI:10.1016/j.omto.2020.06.007.
[38] Chen HT,Li Y,Li L,et al.YTHDC1 gene polymorphisms and hepatoblastoma susceptibility in Chinese children:a seven-center case-control study[J].J Gene Med,2020,22(11):e3249.DOI:10.1002/jgm.3249.
[39] De Ioris M,Brugieres L,Zimmermann A,et al.Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis:the SIOPEL group experience[J].Eur J Cancer,2008,44(4):545-550.DOI:10.1016/j.ejca.2007.11.022.
[40] Ge LC,Zhang N,Chen ZJ,et al.Level of N6-methyladenosine in peripheral blood RNA:a novel predictive biomarker for gastric cancer[J].Clin Chem,2020,66(2):342-351.DOI:10.1093/clinchem/hvz004.
[41] Pei YQ,Lou XY,Li KX,et al.Peripheral blood leukocyte N6-methyladenosine is a noninvasive biomarker for non-small-cell lung carcinoma[J].Onco Targets Ther,2020,13:11913-11921.DOI:10.2147/OTT.S267344.
[42] Xiao H,Fan XB,Zhang R,et al.Upregulated N6-methyladenosine RNA in peripheral blood:potential diagnostic biomarker for breast cancer[J].Cancer Res Treat,2021,53(2):399-408.DOI:10.4143/crt.2020.870.
[43] Bedi RK,Huang DZ,Eberle SA,et al.Small-molecule inhibitors of METTL3,the major human epitranscriptomic writer[J].Chem Med Chem,2020,15(9):744-748.DOI:10.1002/cmdc.202000011.
[44] 俞星雨,顾松,李云洁,等.肝母细胞瘤Wnt/β-catenin信号通路研究进展[J].临床小儿外科杂志,2022,21(7):688-691.DOI:10.3760/cma.j.cn101785-202107049-018. Yu XY,Gu S,Li YJ,et al.Recent advance of Wnt/β-catenin signaling pathway in hepatoblastoma[J].J Clin Ped Sur,2022,21(7):688-691.DOI:10.3760/cma.j.cn101785-202107049-018.

Memo

收稿日期:2022-9-24。
基金项目:国家自然科学基金(82072375; 82172357);2021年度国家临床重点专科建设项目[沪卫医(2021)99号]
通讯作者:顾松,Email:gusong@shsmu.edu.cn

Last Update: 1900-01-01